Halozyme Therapeutics and Avid Bioservices have expanded their commercial supply agreements and entered a long-term strategic relationship. Halozyme has also designated Avid as a preferred supplier for future products requiring Avid’s process development and biomanufacturing capabilities. Avid has manufactured commercial product for Halozyme since 2005 in the company’s cGMP facility.

As part of the new agreements, the companies extended their existing commercial supply agreement for recombinant human hyaluronidase (rHuPH20), used in two of Halozyme’s marketed products, Hylenex and Cumulase. In addition, the companies signed a new commercial supply agreement for additional rHuPH20 products. Financial terms were not disclosed.

“We are delighted to extend these supply agreements, and expand our long-term relationship with Halozyme as we partner with them to support their current and future commercial and clinical process development and biomanufacturing needs,” said Christopher E. Eso, Avid’s vice president, business operations.”Our solid client relationships and dedicated team at Avid have been critical to ensuring our clients’ success.”

Additionally, Halozyme has entered into a new commercial supply agreement with Cook Pharmica for the manufacture of rHuPH20. This agreement is expected to cover the commercial production of rHuPH20 to be used in the manufacture of both current products as well as certain partnered product candidates such as subcutaneous Herceptin and Gammagard with rHuPH20, both currently in Phase III development.

“We are pleased to strengthen our already robust supply chain for rHuPH20 by securing these commercial supply agreements to support existing products as well as exciting partnered product candidates such as subcutaneous Herceptin and Gammagard with rHuPH20,” stated Jonathan E. Lim, M.D., Halozyme’s president and chief executive officer.